These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 38289431)

  • 1. An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review.
    Sabt A; Tawfik HO; Khaleel EF; Badi RM; Ibrahim HAA; Elkaeed EB; Eldehna WM
    Mol Divers; 2024 Jan; ():. PubMed ID: 38289431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells.
    Mohammed I; Hampton SE; Ashall L; Hildebrandt ER; Kutlik RA; Manandhar SP; Floyd BJ; Smith HE; Dozier JK; Distefano MD; Schmidt WK; Dore TM
    Bioorg Med Chem; 2016 Jan; 24(2):160-78. PubMed ID: 26706114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells.
    Bergo MO; Leung GK; Ambroziak P; Otto JC; Casey PJ; Young SG
    J Biol Chem; 2000 Jun; 275(23):17605-10. PubMed ID: 10747846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and pharmacologic analyses of the role of Icmt in Ras membrane association and function.
    Svensson AW; Casey PJ; Young SG; Bergo MO
    Methods Enzymol; 2006; 407():144-59. PubMed ID: 16757321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
    Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation.
    Lau HY; Wang M
    Small GTPases; 2020 Jul; 11(4):271-279. PubMed ID: 29261009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of chronically active ras: potential for treatment of human malignancies.
    Blum R; Cox AD; Kloog Y
    Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):31-47. PubMed ID: 18289122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptides That Block RAS-p21 Protein-Induced Cell Transformation.
    Pincus MR; Lin B; Patel P; Gabutan E; Zohar N; Bowne WB
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Ras-SOS Interactions.
    Lu S; Jang H; Zhang J; Nussinov R
    ChemMedChem; 2016 Apr; 11(8):814-21. PubMed ID: 26630662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting K-Ras Mutations Show Promise Towards Ending Ras's "Undruggable" Era.
    Adams PD; Muhoza D
    Protein Pept Lett; 2022; 29(12):1007-1015. PubMed ID: 36200189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).
    Li N; Liu CF; Zhang W; Rao GW
    Curr Med Chem; 2023 Nov; ():. PubMed ID: 37936461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) Leads to Progressive Loss of Photoreceptor Function.
    Christiansen JR; Pendse ND; Kolandaivelu S; Bergo MO; Young SG; Ramamurthy V
    J Neurosci; 2016 May; 36(18):5107-14. PubMed ID: 27147662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An orthosteric inhibitor of the RAS-SOS interaction.
    Nickerson S; Joy ST; Arora PS; Bar-Sagi D
    Enzymes; 2013; 34 Pt. B():25-39. PubMed ID: 25034099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
    Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
    Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.
    Wahlstrom AM; Cutts BA; Liu M; Lindskog A; Karlsson C; Sjogren AK; Andersson KM; Young SG; Bergo MO
    Blood; 2008 Aug; 112(4):1357-65. PubMed ID: 18502828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
    Kumar SU; Priya Doss CG
    Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis.
    Jeng HH; Taylor LJ; Bar-Sagi D
    Nat Commun; 2012; 3():1168. PubMed ID: 23132018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
    Tamanoi F; Lu J
    Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.